Don't miss Alto at these September investor events: Sept. 9 | Alto Investor Day focused on ALTO-100 in #MajorDepressiveDisorder Sept. 10-11 | Baird Global Healthcare conference Sept. 17-19 | Cantor Fitzgerald Annual Healthcare Conference Sept. 26 | Cowen Inc. 4th Annual Novel Mechanisms in Neuropsychiatry Summit More details here: https://bit.ly/47c9VcW
Alto Neuroscience
Biotechnology
Los Altos, CA 17,426 followers
Precision medicine for the brain is here.
About us
Alto Neuroscience is redefining psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective medicines, helping patients get better faster. Alto's Precision Psychiatry Platform™ measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.
- Website
-
http://www.altoneuroscience.com
External link for Alto Neuroscience
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Los Altos, CA
- Type
- Public Company
- Founded
- 2019
Locations
-
Primary
Los Altos, CA 94022, US
Employees at Alto Neuroscience
Updates
-
Meet Kollin Baer, a Senior Accountant here at Alto. In his day-to-day work, Kollin enjoys building our finance function while partnering with clinical and data science to support operations. When Kollin is not in the office, he enjoys exploring the outdoors! 🏔️ #MeetTheTeam
-
-
“I believe we’re actually much closer to a solution than we give ourselves credit for.” 🎧 Our CEO Amit Etkin discusses the intersection of neurotechnology & #psychiatry to approach treatments for #MentalHealth disorders on the latest episode of the Neurotech Pub Podcast. Listen here: https://bit.ly/3T4X6v6
-
-
Did you know that #BipolarDepression affects 5.7 million adults, or about 2.6% of the U.S. population? Those impacted need innovative treatment options, as the only available medications are antipsychotics, which carry limited efficacy and substantial side effects. With funding from Wellcome Trust, we recently initiated a Phase 2b trial of our lead product candidate ALTO-100 to potentially treat bipolar depression through our #PrecisionPsychiatry approach. Learn more about our ongoing trials here: https://bit.ly/4dzLlF2
-
-
Congratulations to our chief executive officer, Dr. Amit Etkin, chief medical officer, Dr. Adam Savitz, and chief development officer, Jessica Powell, on your co-authored review in Neuropsychopharmacology. Read more about opportunities to use neuroimaging to de-risk #DrugDevelopment and improve clinical outcomes in #psychiatry here: https://rdcu.be/dRAQm
-
-
Alto Neuroscience reposted this
Excited to see our review at Neuropsychopharmacology published today, co-written with two of our leaders at Alto Neuroscience, Adam Savitz and Jessica Powell! We provide a perspective for how different types of neuroimaging (EEG, MRI, PET) can be used at various stages of drug development to de-risk what is currently a low-odds trial-and-error process not directly guided by human neurobiology. "Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective" read it here (open access): https://rdcu.be/dRAQm
-
For too long, #psychiatry has operated with a trial-and-error approach. This process can take time, and time can have consequences. The era of #PrecisionPsychiatry is here, and at Alto, we are working to bring these personalized treatments to people who need them most. Learn more about our story here: https://bit.ly/4fzolI0
-
Meet Lisa Schultze, Ph.D., our Senior Director of Drug Manufacturing! With 35+ years developing small molecule APIs in #biopharma, she's achieved 10 FDA approvals. Lisa thrives on the daily challenges of CMC & supply chain, and unwinds from work with her two pups. 🐶 #MeetTheTeam
-
-
At NYSE’s AI X BIO event, our CEO Amit Etkin joined a dynamic group of leaders to discuss recent advances in computational biology and Alto's industry-leading #PrecisionPsychiatry approach.
🧬 The AI x Bio Summit brought together founders, investors, researchers and more to have open discussions and debates, advancing the field of computational biology with the aim of impacting clinical outcomes and saving lives. Decoding Bio
-
Today we shared our second quarter 2024 financial results & recent business highlights. Read more: https://bit.ly/3YK9Db8